1
|
Byeon H, Gc P, Hannan SA, Alghayadh FY, Soomar AM, Soni M, Bhatt MW. Deep neural network model for enhancing disease prediction using auto encoder based broad learning. SLAS Technol 2024; 29:100145. [PMID: 38750819 DOI: 10.1016/j.slast.2024.100145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2024] [Revised: 04/10/2024] [Accepted: 05/12/2024] [Indexed: 05/25/2024]
Abstract
Bioinformatics and Healthcare Integration Disease prediction models have been revolutionized by Big Data. These models, which make use of extensive medical data, predict illnesses before symptoms appear. Deep neural networks are well-known for their ability to increase accuracy by extending the network's depth and modifying weights through gradient descent. Traditional approaches, however, are hindered by issues such as gradient instability and delayed training. As a substitute, the Broad Learning (BL) system is introduced, which avoids gradient descent in favor of quick reconstruction by incremental learning. However, BL has trouble extracting complicated features from medical data, which makes it perform poorly in cases involving complex healthcare. We suggest ABL, which combines the effectiveness of BL with the noise reduction of Denoising Auto Encoder (AE), to address this. Robust feature extraction is an area in which the hybrid model shines, especially in intricate medical environments. Accuracy of up to 98.50 % is achieved by remarkable results from validation using a variety of datasets. The ability of ABL to quickly adapt through incremental learning suggests that it may be used to forecast diseases in complicated healthcare contexts with agility and accuracy.
Collapse
Affiliation(s)
- Haewon Byeon
- Department of AI and Software, Inje University, Gimhae 50834, Republic of Korea; Inje University Medical Big Data Research Center, Gimhae 50834, Republic of Korea
| | - Prashant Gc
- Department of Computer Science, Texas Tech University, Lubbock 79409, USA
| | - Shaikh Abdul Hannan
- Department of Computer Science and Information Technology, Albaha University, Albaha, Kingdom of Saudi Arabia
| | - Faisal Yousef Alghayadh
- Computer Science and Information Systems Department, College of Applied Sciences, AlMaarefa University, Riyadh, Saudi Arabia
| | - Arsalan Muhammad Soomar
- Faculty of Electrical and Control Engineering, Gdańsk University of Technology, Gdańsk, Poland
| | - Mukesh Soni
- Dr. D. Y. Patil Vidyapeeth, Pune, Dr. D. Y. Patil School of Science & Technology, Tathawade, Pune, India
| | | |
Collapse
|
2
|
Fernandez-Vega V, Hou S, Plenker D, Tiriac H, Baillargeon P, Shumate J, Scampavia L, Seldin J, Souza GR, Tuveson DA, Spicer TP. Lead identification using 3D models of pancreatic cancer. SLAS DISCOVERY : ADVANCING LIFE SCIENCES R & D 2022; 27:159-166. [PMID: 35306207 PMCID: PMC10258910 DOI: 10.1016/j.slasd.2022.03.002] [Citation(s) in RCA: 17] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/04/2022] [Accepted: 03/14/2022] [Indexed: 01/07/2023]
Abstract
Recent technological advances have enabled 3D tissue culture models for fast and affordable HTS. We are no longer bound to 2D models for anti-cancer agent discovery, and it is clear that 3D tumor models provide more predictive data for translation of preclinical studies. In a previous study, we validated a microplate 3D spheroid-based technology for its compatibility with HTS automation. Small-scale screens using approved drugs have demonstrated that drug responses tend to differ between 2D and 3D cancer cell proliferation models. Here, we applied this 3D technology to the first ever large-scale screening effort completing HTS on over 150K molecules against primary pancreatic cancer cells. It is the first demonstration that a screening campaign of this magnitude using clinically relevant, ex-vivo 3D pancreatic tumor models established directly from biopsy, can be readily achieved in a fashion like traditional drug screen using 2D cell models. We identified four unique series of compounds with sub micromolar and even low nanomolar potency against a panel of patient derived pancreatic organoids. We also applied the 3D technology to test lead efficacy in autologous cancer associated fibroblasts and found a favorable profile for better efficacy in the cancer over wild type primary cells, an important milestone towards better leads. Importantly, the initial leads have been further validated in across multiple institutes with concordant outcomes. The work presented here represents the genesis of new small molecule leads found using 3D models of primary pancreas tumor cells.
Collapse
Affiliation(s)
- Virneliz Fernandez-Vega
- The Scripps Research Institute Molecular Screening Center, Department of Molecular Medicine, Scripps Florida, Jupiter, FL, USA
| | - Shurong Hou
- The Scripps Research Institute Molecular Screening Center, Department of Molecular Medicine, Scripps Florida, Jupiter, FL, USA
| | - Dennis Plenker
- Cancer Center, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, USA
| | - Hervé Tiriac
- University of San Diego, California, Moores Cancer Center, Department of Surgery, San Diego, CA, USA
| | - Pierre Baillargeon
- The Scripps Research Institute Molecular Screening Center, Department of Molecular Medicine, Scripps Florida, Jupiter, FL, USA
| | - Justin Shumate
- The Scripps Research Institute Molecular Screening Center, Department of Molecular Medicine, Scripps Florida, Jupiter, FL, USA
| | - Louis Scampavia
- The Scripps Research Institute Molecular Screening Center, Department of Molecular Medicine, Scripps Florida, Jupiter, FL, USA
| | - Jan Seldin
- Greiner Bio-One North America, Inc., Monroe, NC, USA
| | | | - David A Tuveson
- Cancer Center, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, USA
| | - Timothy P Spicer
- The Scripps Research Institute Molecular Screening Center, Department of Molecular Medicine, Scripps Florida, Jupiter, FL, USA.
| |
Collapse
|
3
|
Ulloa-Aguirre A, Zariñán T, Gutiérrez-Sagal R, Tao YX. Targeting trafficking as a therapeutic avenue for misfolded GPCRs leading to endocrine diseases. Front Endocrinol (Lausanne) 2022; 13:934685. [PMID: 36093106 PMCID: PMC9452723 DOI: 10.3389/fendo.2022.934685] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/02/2022] [Accepted: 07/13/2022] [Indexed: 02/05/2023] Open
Abstract
G protein-coupled receptors (GPCRs) are plasma membrane proteins associated with an array of functions. Mutations in these receptors lead to a number of genetic diseases, including diseases involving the endocrine system. A particular subset of loss-of-function mutant GPCRs are misfolded receptors unable to traffic to their site of function (i.e. the cell surface plasma membrane). Endocrine disorders in humans caused by GPCR misfolding include, among others, hypo- and hyper-gonadotropic hypogonadism, morbid obesity, familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism, X-linked nephrogenic diabetes insipidus, congenital hypothyroidism, and familial glucocorticoid resistance. Several in vitro and in vivo experimental approaches have been employed to restore function of some misfolded GPCRs linked to endocrine disfunction. The most promising approach is by employing pharmacological chaperones or pharmacoperones, which assist abnormally and incompletely folded proteins to refold correctly and adopt a more stable configuration to pass the scrutiny of the cell's quality control system, thereby correcting misrouting. This review covers the most important aspects that regulate folding and traffic of newly synthesized proteins, as well as the experimental approaches targeted to overcome protein misfolding, with special focus on GPCRs involved in endocrine diseases.
Collapse
Affiliation(s)
- Alfredo Ulloa-Aguirre
- Red de Apoyo a la Investigación (RAI), National University of Mexico and Instituto Nacional de Ciencias Médicas y Nutrición SZ, Mexico City, Mexico
- *Correspondence: Alfredo Ulloa-Aguirre,
| | - Teresa Zariñán
- Red de Apoyo a la Investigación (RAI), National University of Mexico and Instituto Nacional de Ciencias Médicas y Nutrición SZ, Mexico City, Mexico
| | - Rubén Gutiérrez-Sagal
- Red de Apoyo a la Investigación (RAI), National University of Mexico and Instituto Nacional de Ciencias Médicas y Nutrición SZ, Mexico City, Mexico
| | - Ya-Xiong Tao
- Department of Anatomy, Physiology & Pharmacology, Auburn University College of Veterinary Medicine, Auburn, AL, United States
| |
Collapse
|
4
|
Belostotsky R, Frishberg Y. Novel therapeutic approaches for the primary hyperoxalurias. Pediatr Nephrol 2021; 36:2593-2606. [PMID: 33156410 DOI: 10.1007/s00467-020-04817-8] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/09/2019] [Revised: 08/04/2020] [Accepted: 10/07/2020] [Indexed: 02/06/2023]
Abstract
Loss-of-function mutations in three genes, involved in the metabolic pathway of glyoxylate, result in increased oxalate production and its crystallization in the form of calcium oxalate. This leads to three forms of primary hyperoxaluria-an early-onset inherited kidney disease with wide phenotypic variability ranging from isolated kidney stone events to stage 5 chronic kidney disease in infancy. This review provides a description of metabolic processes resulting in oxalate overproduction and summarizes basic therapeutic approaches. Unfortunately, current treatment of primary hyperoxaluria does not allow the prevention of loss of kidney function or to substantially diminish other symptoms in most patients. However, latest breakthroughs in biotechnology provide new promising directions for drug development. Some of them have already progressed to the level of clinical trials; others are just at the stage of proof of concept. Here we review the most advanced technologies including those that have been harnessed as possible therapeutic modalities.
Collapse
Affiliation(s)
- Ruth Belostotsky
- Division of Pediatric Nephrology, Shaare Zedek Medical Center, 12 Bait Street, 9103102, Jerusalem, Israel
| | - Yaacov Frishberg
- Division of Pediatric Nephrology, Shaare Zedek Medical Center, 12 Bait Street, 9103102, Jerusalem, Israel. .,Hebrew University School of Medicine, Jerusalem, Israel.
| |
Collapse
|
5
|
Small Molecule-Based Enzyme Inhibitors in the Treatment of Primary Hyperoxalurias. J Pers Med 2021; 11:jpm11020074. [PMID: 33513899 PMCID: PMC7912158 DOI: 10.3390/jpm11020074] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2020] [Revised: 01/21/2021] [Accepted: 01/22/2021] [Indexed: 02/07/2023] Open
Abstract
Primary hyperoxalurias (PHs) are a group of inherited alterations of the hepatic glyoxylate metabolism. PHs classification based on gene mutations parallel a variety of enzymatic defects, and all involve the harmful accumulation of calcium oxalate crystals that produce systemic damage. These geographically widespread rare diseases have a deep impact in the life quality of the patients. Until recently, treatments were limited to palliative measures and kidney/liver transplants in the most severe forms. Efforts made to develop pharmacological treatments succeeded with the biotechnological agent lumasiran, a siRNA product against glycolate oxidase, which has become the first effective therapy to treat PH1. However, small molecule drugs have classically been preferred since they benefit from experience and have better pharmacological properties. The development of small molecule inhibitors designed against key enzymes of glyoxylate metabolism is on the focus of research. Enzyme inhibitors are successful and widely used in several diseases and their pharmacokinetic advantages are well known. In PHs, effective enzymatic targets have been determined and characterized for drug design and interesting inhibitory activities have been achieved both in vitro and in vivo. This review describes the most recent advances towards the development of small molecule enzyme inhibitors in the treatment of PHs, introducing the multi-target approach as a more effective and safe therapeutic option.
Collapse
|
6
|
Sridharan B, Hubbs C, Llamosas N, Kilinc M, Singhera FU, Willems E, Piper DR, Scampavia L, Rumbaugh G, Spicer TP. A Simple Procedure for Creating Scalable Phenotypic Screening Assays in Human Neurons. Sci Rep 2019; 9:9000. [PMID: 31227747 PMCID: PMC6588600 DOI: 10.1038/s41598-019-45265-1] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2019] [Accepted: 06/04/2019] [Indexed: 02/08/2023] Open
Abstract
Neurons created from human induced pluripotent stem cells (hiPSCs) provide the capability of identifying biological mechanisms that underlie brain disorders. IPSC-derived human neurons, or iNs, hold promise for advancing precision medicine through drug screening, though it remains unclear to what extent iNs can support early-stage drug discovery efforts in industrial-scale screening centers. Despite several reported approaches to generate iNs from iPSCs, each suffer from technological limitations that challenge their scalability and reproducibility, both requirements for successful screening assays. We addressed these challenges by initially removing the roadblocks related to scaling of iNs for high throughput screening (HTS)-ready assays. We accomplished this by simplifying the production and plating of iNs and adapting them to a freezer-ready format. We then tested the performance of freezer-ready iNs in an HTS-amenable phenotypic assay that measured neurite outgrowth. This assay successfully identified small molecule inhibitors of neurite outgrowth. Importantly, we provide evidence that this scalable iN-based assay was both robust and highly reproducible across different laboratories. These streamlined approaches are compatible with any iPSC line that can produce iNs. Thus, our findings indicate that current methods for producing iPSCs are appropriate for large-scale drug-discovery campaigns (i.e. >10e5 compounds) that read out simple neuronal phenotypes. However, due to the inherent limitations of currently available iN differentiation protocols, technological advances are required to achieve similar scalability for screens that require more complex phenotypes related to neuronal function.
Collapse
Affiliation(s)
- BanuPriya Sridharan
- The Scripps Research Molecular Screening Center, Department of Molecular Medicine, Scripps Research, Jupiter, Florida, 33458, USA
| | - Christopher Hubbs
- Department of Neuroscience, Scripps Research, Jupiter, Florida, 33458, USA
| | - Nerea Llamosas
- Department of Neuroscience, Scripps Research, Jupiter, Florida, 33458, USA
| | - Murat Kilinc
- Graduate School of Chemical and Biological Sciences, Scripps Research, Jupiter, Florida, 33458, USA
| | - Fakhar U Singhera
- The Scripps Research Molecular Screening Center, Department of Molecular Medicine, Scripps Research, Jupiter, Florida, 33458, USA
| | - Erik Willems
- Cell Biology, Thermo Fisher Scientific, Carlsbad, California, 92008, USA
| | - David R Piper
- Cell Biology, Thermo Fisher Scientific, Carlsbad, California, 92008, USA
| | - Louis Scampavia
- The Scripps Research Molecular Screening Center, Department of Molecular Medicine, Scripps Research, Jupiter, Florida, 33458, USA
| | - Gavin Rumbaugh
- The Scripps Research Molecular Screening Center, Department of Molecular Medicine, Scripps Research, Jupiter, Florida, 33458, USA.
- Department of Neuroscience, Scripps Research, Jupiter, Florida, 33458, USA.
- Graduate School of Chemical and Biological Sciences, Scripps Research, Jupiter, Florida, 33458, USA.
| | - Timothy P Spicer
- The Scripps Research Molecular Screening Center, Department of Molecular Medicine, Scripps Research, Jupiter, Florida, 33458, USA.
| |
Collapse
|
7
|
Baillargeon P, Fernandez-Vega V, Sridharan BP, Brown S, Griffin PR, Rosen H, Cravatt B, Scampavia L, Spicer TP. The Scripps Molecular Screening Center and Translational Research Institute. SLAS DISCOVERY : ADVANCING LIFE SCIENCES R & D 2019; 24:386-397. [PMID: 30682260 PMCID: PMC7724958 DOI: 10.1177/2472555218820809] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
The Scripps Research Molecular Screening Center (SRMSC) was founded in 2004 and comprises more than $22 million of specialized automation. As part of the Translational Research Institute (TRI), it comprises early drug discovery labs and medicinal chemistry. Together with Scripps Research at the La Jolla, California, campus, this represents one of the most competitive academic industrial screening centers worldwide. The SRMSC uses automated platforms, one a screening cell and the other a cherry-picking platform. Matched technologies are available throughout Scripps to allow scientists to develop assays and prepare them for automated screening. The library comprises more than 1 million drug-like compounds, including a proprietary collection of >665,000 molecules. Internal chemistry has included ~40,000 unique compounds that are not found elsewhere. These collections are screened against a myriad of disease targets, including cell-based and biochemical assays that are provided by Scripps faculty or from global investigators. Scripps has proven competence in all detection formats, including high-content analysis, fluorescence, bioluminescence resonance energy transfer (BRET), time-resolved fluorescence resonance energy transfer (TR-FRET), fluorescence polarization (FP), luminescence, absorbance, AlphaScreen, and Ca++ signaling. These technologies are applied to NIH-derived collaborations as well as biotech and pharma initiatives. The SRMSC and TRI are recognized for discovering multiple leads, including Ozanimod.
Collapse
Affiliation(s)
- Pierre Baillargeon
- Department of Molecular Medicine, Scripps Research Florida, 130 Scripps Way, Jupiter, Florida, USA
| | - Virneliz Fernandez-Vega
- Department of Molecular Medicine, Scripps Research Florida, 130 Scripps Way, Jupiter, Florida, USA
| | - Banu Priya Sridharan
- Department of Molecular Medicine, Scripps Research Florida, 130 Scripps Way, Jupiter, Florida, USA
| | - Steven Brown
- Department of Molecular Medicine, Scripps Research California, 10550 North Torrey Pines Road, La Jolla, California 92037
| | - Patrick R. Griffin
- Department of Molecular Medicine, Scripps Research Florida, 130 Scripps Way, Jupiter, Florida, USA
| | - Hugh Rosen
- Department of Molecular Medicine, Scripps Research California, 10550 North Torrey Pines Road, La Jolla, California 92037
| | - Benjamin Cravatt
- Department of Molecular Medicine, Scripps Research California, 10550 North Torrey Pines Road, La Jolla, California 92037
| | - Louis Scampavia
- Department of Molecular Medicine, Scripps Research Florida, 130 Scripps Way, Jupiter, Florida, USA
| | - Timothy P. Spicer
- Department of Molecular Medicine, Scripps Research Florida, 130 Scripps Way, Jupiter, Florida, USA
| |
Collapse
|
8
|
Weigert A, Martin-Higueras C, Hoppe B. Novel therapeutic approaches in primary hyperoxaluria. Expert Opin Emerg Drugs 2018; 23:349-357. [PMID: 30540923 DOI: 10.1080/14728214.2018.1552940] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Introduction: Currently, three types of primary hyperoxaluria (PH I-III) are known, all based on different gene-mutations affecting the glyoxylate metabolism in the liver. Disease hallmark is an increased endogenous oxalate production and thus massively elevated urinary excretion of oxalate and other type-specific metabolites. Hyperoxaluria induces the formation of calcium-oxalate kidney stones and/or nephrocalcinosis. In addition to that, a chronic inflammasome activation by hyperoxaluria per se, often leads to an early deterioration of kidney function, regularly resulting in end-stage renal disease (ESRD) at least in patients with type I PH. Except for vitamin B6 treatment in PH I, therapeutic regimen nowadays consists only of supportive measures, like significantly increased fluid intake and medication increasing the urinary solubility like alkaline citrate. Areas covered: Disease burden can be severe, and both clinicians and scientist are eager in finding new therapeutic approaches. The currently ongoing clinical studies and promising research in this field are reported in this paper. To present a complete overview, we searched electronic databases, like Clinical trial gov, National Center for Biotechnology Information PubMed, congress reports, press releases and personal information acquired at congresses and conventions. Searches were conducted using the following medical headings: (primary) hyperoxaluria, PH, therapy, treatment and research. Expert opinion: There is light on the horizon that new treatment options will be available in due time, as there are several promising therapeutic agents currently under investigation, some being at the first levels of drug development, but some already in ongoing clinical trials (phase I-III).
Collapse
Affiliation(s)
- Alexander Weigert
- a Division of Pediatric Nephrology , University Childrens Hospital, Universitatsklinikum Bonn , Bonn , Germany
| | - Christina Martin-Higueras
- a Division of Pediatric Nephrology , University Childrens Hospital, Universitatsklinikum Bonn , Bonn , Germany.,b Institute of Experimental Immunology , University Hospital of the Rheinische Friedrich-Wilhelms-University , Bonn , Germany
| | - Bernd Hoppe
- a Division of Pediatric Nephrology , University Childrens Hospital, Universitatsklinikum Bonn , Bonn , Germany
| |
Collapse
|
9
|
Tao YX, Conn PM. Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases. Physiol Rev 2018; 98:697-725. [PMID: 29442594 DOI: 10.1152/physrev.00029.2016] [Citation(s) in RCA: 67] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
After synthesis, proteins are folded into their native conformations aided by molecular chaperones. Dysfunction in folding caused by genetic mutations in numerous genes causes protein conformational diseases. Membrane proteins are more prone to misfolding due to their more intricate folding than soluble proteins. Misfolded proteins are detected by the cellular quality control systems, especially in the endoplasmic reticulum, and proteins may be retained there for eventual degradation by the ubiquitin-proteasome system or through autophagy. Some misfolded proteins aggregate, leading to pathologies in numerous neurological diseases. In vitro, modulating mutant protein folding by altering molecular chaperone expression can ameliorate some misfolding. Some small molecules known as chemical chaperones also correct mutant protein misfolding in vitro and in vivo. However, due to their lack of specificity, their potential as therapeutics is limited. Another class of compounds, known as pharmacological chaperones (pharmacoperones), binds with high specificity to misfolded proteins, either as enzyme substrates or receptor ligands, leading to decreased folding energy barriers and correction of the misfolding. Because many of the misfolded proteins are misrouted but do not have defects in function per se, pharmacoperones have promising potential in advancing to the clinic as therapeutics, since correcting routing may ameliorate the underlying mechanism of disease. This review will comprehensively summarize this exciting area of research, surveying the literature from in vitro studies in cell lines to transgenic animal models and clinical trials in several protein misfolding diseases.
Collapse
Affiliation(s)
- Ya-Xiong Tao
- Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University , Auburn, Alabama ; and Departments of Internal Medicine and Cell Biology, Texas Tech University Health Science Center , Lubbock, Texas
| | - P Michael Conn
- Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University , Auburn, Alabama ; and Departments of Internal Medicine and Cell Biology, Texas Tech University Health Science Center , Lubbock, Texas
| |
Collapse
|
10
|
Hou S, Tiriac H, Sridharan BP, Scampavia L, Madoux F, Seldin J, Souza GR, Watson D, Tuveson D, Spicer TP. Advanced Development of Primary Pancreatic Organoid Tumor Models for High-Throughput Phenotypic Drug Screening. SLAS DISCOVERY : ADVANCING LIFE SCIENCES R & D 2018; 23:574-584. [PMID: 29673279 PMCID: PMC6013403 DOI: 10.1177/2472555218766842] [Citation(s) in RCA: 94] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/19/2017] [Revised: 02/26/2018] [Accepted: 03/05/2018] [Indexed: 12/30/2022]
Abstract
Traditional high-throughput drug screening in oncology routinely relies on two-dimensional (2D) cell models, which inadequately recapitulate the physiologic context of cancer. Three-dimensional (3D) cell models are thought to better mimic the complexity of in vivo tumors. Numerous methods to culture 3D organoids have been described, but most are nonhomogeneous and expensive, and hence impractical for high-throughput screening (HTS) purposes. Here we describe an HTS-compatible method that enables the consistent production of organoids in standard flat-bottom 384- and 1536-well plates by combining the use of a cell-repellent surface with a bioprinting technology incorporating magnetic force. We validated this homogeneous process by evaluating the effects of well-characterized anticancer agents against four patient-derived pancreatic cancer KRAS mutant-associated primary cells, including cancer-associated fibroblasts. This technology was tested for its compatibility with HTS automation by completing a cytotoxicity pilot screen of ~3300 approved drugs. To highlight the benefits of the 3D format, we performed this pilot screen in parallel in both the 2D and 3D assays. These data indicate that this technique can be readily applied to support large-scale drug screening relying on clinically relevant, ex vivo 3D tumor models directly harvested from patients, an important milestone toward personalized medicine.
Collapse
Affiliation(s)
- Shurong Hou
- The Scripps Research Institute Molecular
Screening Center, Department of Molecular Medicine, Scripps Florida, Jupiter, FL,
USA
- These authors contributed equally to
this work
| | - Hervé Tiriac
- Cancer Center, Cold Spring Harbor
Laboratory, Cold Spring Harbor, NY, USA
- These authors contributed equally to
this work
| | - Banu Priya Sridharan
- The Scripps Research Institute Molecular
Screening Center, Department of Molecular Medicine, Scripps Florida, Jupiter, FL,
USA
| | - Louis Scampavia
- The Scripps Research Institute Molecular
Screening Center, Department of Molecular Medicine, Scripps Florida, Jupiter, FL,
USA
| | - Franck Madoux
- The Scripps Research Institute Molecular
Screening Center, Department of Molecular Medicine, Scripps Florida, Jupiter, FL,
USA
- Amgen, Inc., Thousand Oaks, CA,
USA
| | - Jan Seldin
- Greiner Bio-One North America, Inc.,
Monroe, NC, USA
| | - Glauco R. Souza
- Nano3D Biosciences, Inc. and University
of Texas Health Science Center at Houston, Houston, TX, USA
| | | | - David Tuveson
- Cancer Center, Cold Spring Harbor
Laboratory, Cold Spring Harbor, NY, USA
- Co-communicated by D.T. and T.P.S
| | - Timothy P. Spicer
- The Scripps Research Institute Molecular
Screening Center, Department of Molecular Medicine, Scripps Florida, Jupiter, FL,
USA
- Co-communicated by D.T. and T.P.S
| |
Collapse
|
11
|
Belostotsky R, Lyakhovetsky R, Sherman MY, Shkedy F, Tzvi-Behr S, Bar R, Hoppe B, Reusch B, Beck BB, Frishberg Y. Translation inhibition corrects aberrant localization of mutant alanine-glyoxylate aminotransferase: possible therapeutic approach for hyperoxaluria. J Mol Med (Berl) 2018; 96:621-630. [PMID: 29777253 DOI: 10.1007/s00109-018-1651-8] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2017] [Revised: 05/03/2018] [Accepted: 05/09/2018] [Indexed: 01/28/2023]
Abstract
Primary hyperoxaluria type 1 is a severe kidney stone disease caused by abnormalities of the peroxisomal alanine-glyoxylate aminotransferase (AGT). The most frequent mutation G170R results in aberrant mitochondrial localization of the active enzyme. To evaluate the population of peroxisome-localized AGT, we developed a quantitative Glow-AGT assay based on the self-assembly split-GFP approach and used it to identify drugs that can correct mislocalization of the mutant protein. In line with previous reports, the Glow-AGT assay showed that mitochondrial transport inhibitors DECA and monensin increased peroxisomal localization of the mutant. Here, we demonstrate that prolonged treatment with the translation elongation inhibitor emetine, a medicinal alkaloid used in treatment of amoebiasis, corrected G170R-AGT mislocalization. Furthermore, emetine reduced the augmented oxalate level in culture media of patient-derived hepatocytes bearing the G170R mutation. A distinct translation inhibitor GC7 had a similar effect on the mutant Glow-AGT relocalization indicating that mild translation inhibition is a promising therapeutic approach for primary hyperoxaluria type 1 caused by AGT misfolding/mistargeting. KEY MESSAGES • There is no effective conservative treatment to decrease oxalate production in PH1 patients. • Chemical chaperones rescue mislocalization of mutant AGT and reduce oxalate levels. • We have developed an assay for precise monitoring of the peroxisomal AGT. • Inhibition of translation by emetine reroutes the mutant protein to peroxisome. • Mild translation inhibition is a promising cure for conformational disorders.
Collapse
Affiliation(s)
- Ruth Belostotsky
- Division of Pediatric Nephrology, Shaare Zedek Medical Center, Shmuel Bait Street, 91031, Jerusalem, Israel.
| | - Roman Lyakhovetsky
- Division of Pediatric Nephrology, Shaare Zedek Medical Center, Shmuel Bait Street, 91031, Jerusalem, Israel.,Medical Scientific Unit, Teva Pharmaceutical Industries, Petah Tikva, Israel
| | | | - Fanny Shkedy
- Division of Pediatric Nephrology, Shaare Zedek Medical Center, Shmuel Bait Street, 91031, Jerusalem, Israel
| | - Shimrit Tzvi-Behr
- Division of Pediatric Nephrology, Shaare Zedek Medical Center, Shmuel Bait Street, 91031, Jerusalem, Israel
| | - Roi Bar
- Division of Pediatric Nephrology, Shaare Zedek Medical Center, Shmuel Bait Street, 91031, Jerusalem, Israel
| | - Bernd Hoppe
- Department of Pediatrics, University Medical Center, Bonn, Germany
| | - Björn Reusch
- Institute of Human Genetics, Cologne, Germany.,Center for Molecular Medicine Cologne, Cologne, Germany
| | - Bodo B Beck
- Institute of Human Genetics, Cologne, Germany.,Center for Molecular Medicine Cologne, Cologne, Germany
| | - Yaacov Frishberg
- Division of Pediatric Nephrology, Shaare Zedek Medical Center, Shmuel Bait Street, 91031, Jerusalem, Israel
| |
Collapse
|
12
|
Oppici E, Dindo M, Conter C, Borri Voltattorni C, Cellini B. Folding Defects Leading to Primary Hyperoxaluria. Handb Exp Pharmacol 2018; 245:313-343. [PMID: 29071511 DOI: 10.1007/164_2017_59] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Protein misfolding is becoming one of the main mechanisms underlying inherited enzymatic deficits. This review is focused on primary hyperoxalurias, a group of disorders of glyoxylate detoxification associated with massive calcium oxalate deposition mainly in the kidneys. The most common and severe form, primary hyperoxaluria Type I, is due to the deficit of liver peroxisomal alanine/glyoxylate aminotransferase (AGT). Various studies performed in the last decade clearly evidence that many pathogenic missense mutations prevent the AGT correct folding, leading to various downstream effects including aggregation, increased degradation or mistargeting to mitochondria. Primary hyperoxaluria Type II and primary hyperoxaluria Type III are due to the deficit of glyoxylate reductase/hydroxypyruvate reductase (GRHPR) and 4-hydroxy-2-oxoglutarate aldolase (HOGA1), respectively. Although the molecular features of pathogenic variants of GRHPR and HOGA1 have not been investigated in detail, the data available suggest that some of them display folding defects. Thus, primary hyperoxalurias can be ranked among protein misfolding disorders, because in most cases the enzymatic deficit is due to the inability of each enzyme to reach its native and functional conformation. It follows that molecules able to improve the folding yield of the enzymes involved in each disease form could represent new therapeutic strategies.
Collapse
Affiliation(s)
- Elisa Oppici
- Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biological Chemistry, University of Verona, Strada Le Grazie 8, 37134, Verona, Italy
| | - Mirco Dindo
- Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biological Chemistry, University of Verona, Strada Le Grazie 8, 37134, Verona, Italy
| | - Carolina Conter
- Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biological Chemistry, University of Verona, Strada Le Grazie 8, 37134, Verona, Italy
| | - Carla Borri Voltattorni
- Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biological Chemistry, University of Verona, Strada Le Grazie 8, 37134, Verona, Italy.
| | - Barbara Cellini
- Department of Experimental Medicine, University of Perugia, Piazzale Gambuli 1, 06132, Perugia, Italy.
| |
Collapse
|